Information Provided By: 
Fly News Breaks for October 8, 2019
FOMX
Oct 8, 2019 | 08:42 EDT
Cantor Fitzgerald analyst Louise Chen says her 25 physician survey supports her positive view on the market opportunity for Foamix's FMX10. If approved, FMX101 has the potential to address a significant unmet need in the treatment of moderate-to-severe acne, which remains a difficult condition, Chen tells investors in a research note. She reiterates an Overweight rating on Foamix shares with a $15 price target ahead of the upcoming FDA action date for FMX101 on October 20. The analyst thinks the Street is underestimating the uptake of acne drugs.
News For FOMX From the Last 2 Days
There are no results for your query FOMX
